Welcome to our dedicated page for Relief Hldg news (Ticker: RLFTF), a resource for investors and traders seeking the latest updates and insights on Relief Hldg stock.
Relief Therapeutics Holding SA (OTCQB: RLFTF), historically known as Relief Therapeutics, regularly issues news updates covering its biopharmaceutical pipeline, corporate milestones, and, more recently, its transformation into MindMaze Therapeutics Holding SA through a business combination with NeuroX Group SA. Company press releases describe a focus on rare dermatological, metabolic, and respiratory diseases, along with digital neurotherapeutics and an AI-powered brain health platform following the combination.
News items for RLFTF include clinical and regulatory developments such as FDA designations and meeting outcomes for RLF-TD011 in epidermolysis bullosa, and pivotal bioequivalence study results for RLF-OD032, a liquid sapropterin formulation for phenylketonuria. Investors and observers can also find updates on corporate governance events like annual general meetings, half-year and annual report publications, and shareholder approvals for strategic transactions.
Coverage further extends to transaction-related announcements, including the proposed and completed business combination with NeuroX, details on share exchanges, and the renaming of the company to MindMaze Therapeutics Holding SA. Subsequent communications describe the combined company’s activities in digital neurorehabilitation and neurological care, while noting that it continues to manage Relief’s preexisting biopharmaceutical assets.
By following RLFTF news, readers can track the evolution of Relief’s rare disease programs, its regulatory interactions, and the integration of its portfolio into the broader MindMaze Therapeutics platform. This news stream provides context on how the company positions its therapies and digital technologies within the rare disease and neurology landscapes.
Relief Therapeutics Holding SA has filed a Registration Statement on Form 20-F with the U.S. SEC, aiming to upgrade its Level 1 American Depositary Receipt (ADR) program to Level 2. This move supports Relief's ambition to list on the NASDAQ during the first half of 2022, pending SEC approval and application. Currently, the company's ordinary shares are traded on the SIX Swiss Exchange under the symbol RLF and on OTCQB under RLFTF. The ADRs represent 150 of Relief's ordinary shares and currently trade as RLFTY.
Relief Therapeutics Holding SA announced that its collaboration partner, NRx Pharmaceuticals, reported a favorable safety update on aviptadil, currently being tested in the ACTIV-3b Critical Care Phase 3 study by the NIH. The Independent Data Safety Monitoring Board reviewed 348 patients and found no new safety concerns, allowing the study to continue enrollment aiming for a total of 640 patients. This update supports Relief's lead candidate, RLF-100 (aviptadil), which is in late-stage testing for respiratory deficiencies due to COVID-19.
Relief Therapeutics reported that its partner, NRx Pharmaceuticals, has established a regulatory pathway with Hungarian Health Officials for the emergency use of aviptadil. This program is expected to commence by the end of 2021. Relief is focused on clinical-stage programs, notably advancing RLF-100 (aviptadil) for COVID-19 related respiratory issues. The company also diversifies its pipeline through agreements like the one with Acer Therapeutics for ACER-001 aimed at treating Urea Cycle Disorders.
Relief Therapeutics announces key executive changes aimed at strengthening its leadership team. Nermeen Varawalla has been appointed as Chief Medical Officer, replacing Gilles Della Corte. Varawalla brings over 30 years of experience in the pharmaceutical sector, focusing on clinical trials and regulatory expertise. Jeremy Meinen is promoted to Chief Accounting Officer, while Marco Marotta takes on the role of Chief Business Officer, overseeing business development. These strategic appointments align with Relief's goal to expand its clinical pipeline.
Relief Therapeutics (OTCQB: RLFTF, RLFTY) announced a significant breakthrough in treating Critical COVID-19 with aviptadil, indicating better outcomes compared to remdesivir. An analysis led by Prof. David Schoenfeld showed a 2.5-fold increase in the odds of patients recovering from respiratory failure and a four-fold higher chance of survival at 60 days. This highlights the potential of aviptadil as an effective treatment for severe cases of COVID-19, offering hope in serious disease management.
Relief Therapeutics has entered a collaboration with InveniAI to identify new drug candidates for rare diseases using AI technologies. InveniAI's proprietary AlphaMeld platform will analyze data from regulatory-approved drugs to find potential therapies. Relief will compensate InveniAI with an initial fee, milestone payments, and royalties. The partnership aims to leverage AI for efficient drug development while enhancing Relief's existing capabilities through its subsidiary APR Applied Pharma Research. This collaboration could lead to innovative product concepts for patients with severe conditions.
Relief Therapeutics announced that its collaboration partner, NRx Pharmaceuticals, received notice from the FDA denying Breakthrough Therapy Designation for aviptadil. While this designation could have expedited the review process, it is not a requirement for drug approval. The FDA had previously granted priority and rolling review under Fast Track Designation. NRx emphasized that potential approval remains viable, but acknowledges the need for improved scientific alignment. Relief continues to advance its clinical programs, including RLF-100 for COVID-19 respiratory issues.
Relief Therapeutics announced the effectiveness of its Form F-6 registration statement, launching a Level 1 American Depositary Receipt (ADR) program in the U.S. on November 18, 2021. The ADRs, trading under the symbol RLFTY, will represent 150 ordinary shares of Relief, enabling U.S. investors to trade seamlessly. Although Relief will not generate any immediate proceeds from this program, it aims to transition to a Level 2 or Level 3 ADR program with a potential listing on the Nasdaq in the first half of 2022, though success is not guaranteed.
Relief Therapeutics announced that its collaboration partner, NRx Pharmaceuticals, received a positive response from the U.S. FDA regarding updated manufacturing information for aviptadil. This allows for high-volume production and extends the shelf life of aviptadil from 62 days to 150 days. Relief's lead drug candidate, aviptadil, aims to treat respiratory deficiency in COVID-19 patients and is in late-stage clinical testing. The company also has a diverse development pipeline following recent acquisitions.
Relief Therapeutics provided a corporate update regarding its clinical developments and regulatory activities. The company is advancing RLF-100(TM) (aviptadil) for COVID-19 related respiratory complications, with ongoing trials in Europe and the U.S. Recently, it received authorization for a phase 2 trial for pulmonary sarcoidosis. Relief is also preparing to market its PKU GOLIKE(R) product in the U.S. and expects a decision on ACER-001 by June 2022. Relief holds CHF45 million in cash, projecting to cover operations into late 2023 and aiming for positive cash flow by 2024.